TW202342102A - 治療兒科病症之方法 - Google Patents

治療兒科病症之方法 Download PDF

Info

Publication number
TW202342102A
TW202342102A TW112126603A TW112126603A TW202342102A TW 202342102 A TW202342102 A TW 202342102A TW 112126603 A TW112126603 A TW 112126603A TW 112126603 A TW112126603 A TW 112126603A TW 202342102 A TW202342102 A TW 202342102A
Authority
TW
Taiwan
Prior art keywords
antibody
dose
weeks
seq
response
Prior art date
Application number
TW112126603A
Other languages
English (en)
Chinese (zh)
Inventor
瑪利亞 羅莎莉歐
麥可 A 斯特茲林
威廉 R 崔姆
Original Assignee
美商千禧製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商千禧製藥公司 filed Critical 美商千禧製藥公司
Publication of TW202342102A publication Critical patent/TW202342102A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1777—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW112126603A 2017-04-28 2018-04-27 治療兒科病症之方法 TW202342102A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762492031P 2017-04-28 2017-04-28
US62/492,031 2017-04-28

Publications (1)

Publication Number Publication Date
TW202342102A true TW202342102A (zh) 2023-11-01

Family

ID=62455814

Family Applications (2)

Application Number Title Priority Date Filing Date
TW112126603A TW202342102A (zh) 2017-04-28 2018-04-27 治療兒科病症之方法
TW107114371A TWI811216B (zh) 2017-04-28 2018-04-27 治療兒科病症之方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW107114371A TWI811216B (zh) 2017-04-28 2018-04-27 治療兒科病症之方法

Country Status (13)

Country Link
US (1) US20200179486A1 (https=)
EP (1) EP3615071A2 (https=)
JP (2) JP2020517671A (https=)
KR (2) KR20190141148A (https=)
CN (1) CN110612120A (https=)
AR (1) AR111491A1 (https=)
AU (2) AU2018256840A1 (https=)
BR (1) BR112019022268A2 (https=)
CA (1) CA3061320A1 (https=)
IL (1) IL270201B1 (https=)
MX (4) MX2019012749A (https=)
TW (2) TW202342102A (https=)
WO (1) WO2018200818A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016086147A1 (en) 2014-11-26 2016-06-02 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
JP7778567B2 (ja) * 2019-04-17 2025-12-02 ミレニアム ファーマシューティカルズ， インコーポレイテッド α４β７阻害薬及びＩＬ－２３阻害薬の併用療法
CN115515435A (zh) * 2020-02-11 2022-12-23 沃尔夫森医疗中心 有效治疗溃疡性结肠炎的方法
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法
WO2025177055A1 (en) * 2024-02-20 2025-08-28 Takeda Pharmaceutical Company Limited Combination therapy for treating inflammatory bowel disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
WO1996024673A1 (en) 1995-02-10 1996-08-15 Leukosite, Inc. Mucosal vascular addressins and uses thereof
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6197582B1 (en) 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
NZ566263A (en) 2002-05-24 2009-09-25 Millennium Pharm Inc CCR9 inhibitors and methods of use thereof
KR100874292B1 (ko) 2002-11-18 2008-12-18 케모센트릭스 아릴 술폰아마이드
WO2006026759A2 (en) 2004-09-03 2006-03-09 Genentech, Inc. Humanized anti-beta7 antagonists and uses therefor
EP1948691A1 (en) 2005-11-17 2008-07-30 Millennium Pharmaceuticals, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH a4ß7INTEGRIN
CN103382222B (zh) 2009-03-20 2016-12-28 安姆根有限公司 α-4-β-7异二聚体特异性拮抗剂抗体
MX367097B (es) 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
HK1244229A1 (zh) * 2015-02-26 2018-08-03 F. Hoffmann-La Roche Ag 治疗CROHN病的整联蛋白β7拮抗剂和方法
AU2017234010B2 (en) * 2016-03-14 2024-06-13 Millennium Pharmaceuticals, Inc. Methods of treating or preventing graft versus host disease

Also Published As

Publication number Publication date
TW201842932A (zh) 2018-12-16
MX2024012972A (es) 2024-11-08
WO2018200818A3 (en) 2018-12-06
JP2020517671A (ja) 2020-06-18
US20200179486A1 (en) 2020-06-11
BR112019022268A2 (pt) 2020-05-19
AR111491A1 (es) 2019-07-17
WO2018200818A2 (en) 2018-11-01
WO2018200818A9 (en) 2019-01-17
CN110612120A (zh) 2019-12-24
KR20250134146A (ko) 2025-09-09
AU2025202525A1 (en) 2025-05-01
CA3061320A1 (en) 2018-11-01
MX2024003905A (es) 2024-04-23
RU2019138312A (ru) 2021-05-28
RU2019138312A3 (https=) 2022-02-03
EP3615071A2 (en) 2020-03-04
TWI811216B (zh) 2023-08-11
JP2023113655A (ja) 2023-08-16
KR20190141148A (ko) 2019-12-23
MX2019012749A (es) 2020-02-03
IL270201A (https=) 2019-12-31
MX2024003906A (es) 2024-04-23
AU2018256840A1 (en) 2019-11-07
IL270201B1 (en) 2026-01-01

Similar Documents

Publication Publication Date Title
US20240368263A1 (en) Optimized anti-tl1a antibodies
TWI811216B (zh) 治療兒科病症之方法
JP6297088B2 (ja) Ｐｃｓｋ９アンタゴニスト
JP6668461B2 (ja) 炎症性疾患の処置法
US11440965B2 (en) Anti-OX40 antibody
US20240309104A1 (en) Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
JP7512433B2 (ja) 抗ｐｄ－１抗体
JP2019528285A (ja) 抗ｎｋｇ２ｄ抗体を用いたクローン病の治療方法
CN114630680B (zh) 用于治疗乙型肝炎病毒感染的抗体组合物和方法
JP2019536756A (ja) Ｉｌ−２３ａ抗体を用いて疾患を処置する方法
JP7202893B2 (ja) 炎症性腸疾患を治療する方法
CN119768431A (zh) Igf1r抗体
RU2778567C2 (ru) Способ лечения педиатрических расстройств/заболеваний
EP4153313A1 (en) Anti-sars-cov-2 antibodies and uses thereof
HK40042163B (zh) 优化的抗tl1a抗体
HK40038976A (en) Isolated antibody or antigen binding fragment thereof and use of same in tumor treatment